Qatar Biobank and Qatar Genome Programs Road Map by Althani, A
Volume 6 • Issue 3 • 1000157
J Tissue Sci Eng
ISSN: 2157-7552 JTSE, an open access journal 











Althani, J Tissue Sci Eng 2015, 6:3
http://dx.doi.or/10.4172/2157-7552.1000157
Introduction
Qatar Biobank has been created in order to enable medical research 
on genetic diseases that affect the local population. The Biobank 
aims to collect samples from the general population of Qatar as well 
as information on health and lifestyle factors as an initial step. The 
Biobank is the most ambitious national health initiative undertaken in 
the country with the ultimate objective of preventing, improving teh 
diagnosis, and treatment of genetic or complex diseases in addition to 
understanding how lifestyle factors affect development of disease in this 
population.
The baseline information from 60,000 adults will be collected by 
2019 and will encompass many phenotypic characteristics, including 
sociodemographic information, physical measures, health and lifestyle 
factors, medical history, and blood measurements. The participants will 
be followed up for an average of 5 years for development of diabetes, 
cardiovascular and neurodegenrative diseases. In addition, the data 
from the biobank will be retrspectively linked to participants’ medical 
records in order to elucidate any relationship between phenotypes and 
genotypes. The wealth of data from the Qatar Biobank will be made 
available to local researchers, after an approved application. 
Rationale for the biobank
Complex diseases, e.g., diabetes, heart disease, etc are caused by an 
interplay between environmental factors  and genetic predisposition. 
Current medical treatments for complex diseases are based on clinicla 
data largely from the Western population and large scale trials in 
the Arab region are both scant and not practical (due to the small 
population sizes and lack of infrastructure). In the Gulf region, to 
date, no large scale trials have investigated the aetiological components 
of complex disease. The Qatar Biobank has been set up by the Qatar 
Foundation and the Supreme Council of Health in collaboration with 
Imperial College London, as the first Qatar national population based 
prospective cohort study, and includes the collection of biological 
samples, with long-term storage of data and samples for future research. 
Qatar Biobank will help identify genes and risk factors for diseases 
common in the homogenous Qatari population such as obesity, heart 
disease, diabetes and cancer. Type 2 diabetes presents a special consideration 
for Qatar since 17% of the population suffer from it [1]. The Qatar Biobank 
will thus provide an important resource for the investigation of the 
aetiological factors and their interactions in the development of complex 
diseases. The health information and samples collected by Qatar Biobank 
will allow researchers to better understand diseases that affect the Qatari 
community and may potentially lead to a personalised medical approach 
towards managing this population. Qatar Biobank aims to encourage 
and provide as wide access as possible for local researchers to its data and 
samples for health-related research in the public interest. 
Biobank Cohort
The potential 60,000 participants (adults (≥ 18 years) who are either 
Qatari nationals or long-term residents (lived in Qatar for ≥ 15 years) 
will be assessed between 2019 in Qatar. Blood , urine and saliva samples 
are being collected and stored for future research use. The assessment 
visit comprises of a signed consent; a self-completed questionnaire; brief 
healthcare professional interview; physical and functional measures; 
and collection of blood, urine, and saliva. Multiple aliquots of different 
sample fractions are stored in Qatar Biobank’s laboratory, allowing for a 
wide range of future investigations. 
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Abstract
Qatar Biobank “QBB” is a large-scale, long term medical research initiative for the population of Qatar, which 
will serve as a platform and driver of biomedical research to achieve benefits for Qatar’s communities. Following 
on from the announcement of the Qatar Genome Project in 2013 by Her Highness Sheikha Moza bint Nasser, 
Chairperson of Qatar Foundation “QF”, a National Genome Committee “NGC” is tasked with the role of driving and 
advising the development of the Genome Project in Qatar. To ensure the successful implementation and completion 
of a project of this complexity, it was important to consider carefully the organizational structure of Genome Qatar 
to enable success, so the decision was to establish QG project within the existing framework of the government of 
QBB. A road map constitutes of seven key building blocks, were identified to address the critical success factors 
and be managed and overseen by the Board of Trustee for both QBB and QG program.  The seven building blocks 
are 1-Develop a National Health Information System, 2-Enhancement of the National Biobank, 3-Develop Genomics 
Infrastructure,4- Develop Policy Framework for genomics and precision medicine, 5-Workforce Development ,6- 
Research and Partnership and 7- Clinical/Medical implementation. To successfully accomplish this ambitious role 
a road map is initiated through a pilot phase to establish the infrastructure and human capacity for 12-18 months 
in order to tackle problems, identify loopholes, analyze the needs and optimize systems that are needed for the 
entire Qatar Genome project. The aim is to sequence 1000-3000 genomes to develop a good model of practice for 
regulatory compliant, sample collection and storage, high quality data generation, analysis and annotation pipeline 
development and data warehouse establishment.
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Qatar Biobank will conduct a range of additional phenotyping 
assessments. Data are already available both from a pilot phase, 
completed by 1,209 participants. Over the coming months and years, 
further data will become available from more participants as rates of 
recruitment will be progressively increased in order to achieve a cohort 
of consented individuals broadly representative of the eligible Qatari 
population.
Research Stemming from the Biobank 
Following initial assessment by the executive team, all research 
applications will be appraised  and either approved or rejected by an 
independent Comittee. Advice is sought on any applications raising 
potential ethical issues from the Ethics and Governance Council. Only 
anonymised data are provided to researchers, who must only use it for 
the purposes of the approved research. Researchers must also undertake 
to publish their results and provide details of their methodology, 
derived data, and/or sample assay results for incorporation into the 
Qatar Biobank Database. Qatar Biobank encourages publication of 
results of research stemming from the Biobank. 
Running Qatar Biobank
Success so far in developing and enhancing the resource has relied 
on public willingness to participate in the Qatar Biobank project; close 
engagement with volunteers, funding and governance of the Qatar 
Government; extensive consultation with the scientific and ethical 
committees; and the development of effective methodoly in association 
with Imperial College, UK. 
A roadmap constiuting of seven key factors was identified to 
address the critical success factors for the project. These include:
1. Development of a National Health Information System
2. Enhancement of the National Biobank
3. Development of the Genomics Infrastructure
4. Development of Policy Framework for genomics and precision 
medicine
5. Workforce Development
6. Research and Partnership 
7. Clinical/Medical implementation. 
A key step in achieving the recruitment, characterisation, and 
follow-up of 60,000 participants was the creation of an executive and 
advisory team as well as a strong scientific and management team. This 
facilitated the development of a centralised infrastructure, bespoke 
information technology (IT) systems, and effecient approaches to 
collection and processing of data and samples.
Each initial recruitment visit lasts approximately 179 minutes and 
staff and equipment at the Biobank facilities are set up to cope with the 
flow of 50 pparticipants per day allowing for the recruitment visit time. 
Biological samples arr being processed and handled centrally. Each step 
of the recruitment, assessment, and sample handling process was first 
tested in the pilot phase and modified as necessary. 
Interactions with Participants
So far participants have been recruited through public and private 
employers though most participants were recruited by personal 
recommendations of friends and family. All are requested to provide 
broad consent to use of their anonymised data and samples for any 
health-related research, to be re-contacted for further substudies, and 
for Qatar Biobank to access their health-related records. 
Qatar Biobank keeps its participants involved through providing 
progress updates via its website, enabling them to continue to support 
the project and participate in research over the years ahead.
Participants also receive a summary of their standard measures 
(e.g., blood pressure, body mass index) at the end of each assessment 
visit and are encouraged to seek medical advice or referred if the 
results are outside the normal ranges. Similarly, any incidental imaging 
findings lead to referrals where necessary. In addition, the overall 
findings obtained from the pilot phase and subsequent sequencing 
programme will be used to identify and manage emerging public health 
issues in Qatar.
Ethics and Governance of the Biobank
An independent Ethics and Governance Council oversees 
adherence to the Ethics and Governance Framework and provides 
advice on the interests of research participants and the general public in 
relation to Qatar Biobank.
Institutional Review Board approval is obtained from the Hamad 
Medical Corporation Ethics Committee. The Qatar Biobank Regulations 
and Access Committee will advise the Board, the managing director, 
Qatar Foundation and Supreme Council for Health regarding the best 
practice and implementation of Ethics, Privacy and Access regulation 
as well as provide a forum for joint strategic discussion, considering 
actual and anticipated changes in the scope of research collaborations. 
It will also make recommendations for the most efficient use of QBB 
samples and data internally and externally. 
The Pilot phase
The pilot phase ran between 2012 and 2014 and recruited 
1,209 participants. Phenotypic information was collected from 
each participant, including socio-demographic information, health 
conditions, diet, lifestyle, anthropometry, body composition, bone 
health, cognitive function, grip strength, retinal imaging, total body 
dual energy X-ray absorptiometry (iDXA), and measurements of 
cardiovascular and respiratory function. Samples (urine, saliva and 
blood) were collected from each participant and stored for future use. A 
panel of 66 clinical biomarkers was routinely measured on fresh blood 
samples in all participants. The participants all underwent a 5-stage 
interview and physical and clinic measurement sequence which lasted 
approximately 179 minutes.
The results are due to be published. The pilot phase has 
demonstrated that recruitment and processing of data from large 
number of participants is logistically feasible and the data obtained will 
provide useful information not only on genetic basis of rare or complex 
diseases but also on public health issues threatening the health system 
in Qatar.
Summary
The key lessons learned from establishing Qatar Biobank are that 
this large scale project requires a focesed scientific approach, strong 
communication channels between the various diciplines involved; 
effecient processing and analysis of samples; close partnership with 
supporting organisations (e.g., bioinformatics support); strong 
overseeing scientific, legal and ethical committees, public support as 
well as streamlined governance and ethics infrastructure. 
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The pilot phase is now complete and the sequencing of 60,000 
participants is also now underway. The next steps will be to facilitate 
research by local scientitst and public health stakeholders in order to 
investigate the prevalence of certain diseases in the country as well as 
understand how different diseases are caused by the combination of 
lifestyle, environment, and genes. The aim is to eventually prevent, aid 
diagnosis, and treatment of identified diseases. 
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